Regulatory considerations for preclinical development of anticancer drugs

Cancer Chemotherapy and Pharmacology
J J DeGeorgeS C Tripathi

Abstract

The entry of new anticancer treatments into phase I clinical trials is ordinarily based on relatively modest preclinical data. This report defines the battery of preclinical tests important for assessing safety under an Investigational New Drug application (IND) and outlines a basis for extrapolating starting doses of investigational anticancer drugs in phase I clinical trials from animal toxicity studies. Types of preclinical studies for the support of marketing of a new anticancer drug are also discussed. This report addresses differences and similarities in the preclinical development of cytotoxic drugs (including photosensitizers and targeted delivery products), drugs used chronically (chemopreventive drugs, hormonal drugs, immunomodulators), and drugs intended to enhance the efficacy (MDR-reversing agents and radiation/chemotherapy sensitizers) or diminish the toxicity of currently used anticancer therapies. Factors to consider in the design of preclinical studies of combination therapies, alternative therapies, and adjuvant therapies in the treatment of cancer, and to support changes in clinical formulations or route of administration, are also discussed.

Citations

May 4, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Joseph E Tomaszewski
Feb 6, 2003·Drug Discovery Today·Paul Baldrick
Sep 24, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Tao WangWilliam David McGuinn
Jul 31, 2012·Toxicological Sciences : an Official Journal of the Society of Toxicology·Harvey WongWayne J Fairbrother
Jul 18, 2006·British Journal of Clinical Pharmacology·Shivaani KummarAnthony J Murgo
Jun 5, 2003·Expert Opinion on Therapeutic Targets·Barbara Fingleton
Mar 8, 2012·Nanotoxicology·Venugopalan KasturiranganMohamed K Khan
Apr 14, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Stephan T SternScott E McNeil
Jul 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S RugoGeorge Wilding
Jun 15, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lee S RosenRoy S Herbst
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe Le TourneauLillian L Siu
Oct 1, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OttPatrick Hwu
Feb 27, 2009·Toxicologic Pathology·Christopher J Horvath, Mark N Milton
Aug 24, 2011·Toxicologic Pathology·Rafael Ponce
Jun 15, 1999·Toxicologic Pathology·L H Arp
Sep 1, 2011·International Journal of Toxicology·Susan van TongerenLyn M Wancket
Jan 1, 1997·Journal of Cellular Biochemistry. Supplement·K A JohnsonR DeLap
Mar 14, 2007·Hematological Oncology·Michela Maur, Cristiana Sessa
Jun 10, 2008·The Cancer Journal·Shivaani KummarJames H Doroshow
Oct 14, 2005·Journal of Pharmacokinetics and Pharmacodynamics·Ferdinand RomboutUNKNOWN COST B15 Experts
Nov 11, 1999·British Journal of Cancer·D R NewellT A Connors
Nov 11, 1999·British Journal of Cancer·B Leyland-Jones, C K Grieshaber
Mar 19, 2019·Clinical and Translational Science·Davy ChiodinSarah H Lockwood
Mar 1, 2010·Expert Opinion on Medical Diagnostics·Andrea Staratschek-Jox, Joachim L Schultze
Feb 1, 2007·Current Protocols in Toxicology·Michael A Dorato, Lorrene A Buckley
Nov 2, 2019·Clinical and Translational Science·Mariam A AhmedDaria Stypinski
Apr 1, 2006·Current Protocols in Pharmacology·Michael A Dorato, Lorrene A Buckley
Dec 5, 2018·Journal of Translational Medicine·Joyson J KarakunnelShivaani Kummar
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephan A VeltkampJan H M Schellens
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adrian M Senderowicz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Urology : Official Journal of the Japanese Urological Association
Akira FujisakiTatsuo Morita
JAMA : the Journal of the American Medical Association
Joshua J Gagne, Niteesh K Choudhry
Journal of Colloid and Interface Science
G Gonzalez, F MacRitchie
© 2021 Meta ULC. All rights reserved